Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 5, 2009, Pages 436-441

  Basu, Kaninika ^a   Nair, Arun ^a   Williamson, Peter A ^a   Mukhopadhyay, Somnath ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; BUDESONIDE; CREATININE; HYDROCORTISONE; NITRIC OXIDE; PULMICORT RESPULE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG; BRONCHODILATING AGENT;

ADRENAL SUPPRESSION; AIRWAY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; INFANT; LUNG FUNCTION; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NEBULIZATION; NEBULIZER; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; SOLUBILITY; SORE THROAT; SUSPENSION; TREATMENT DURATION; DRUG EFFECT; LUNG; SOLUTION AND SOLUBILITY; TREATMENT OUTCOME;

ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CROSS-OVER STUDIES; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; SOLUTIONS; SUSPENSIONS; TREATMENT OUTCOME;

EID: 73349122909     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60365-1     Document Type: Article

References (31)

1. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411- 437.
2. Ely L, Roa W, Finlay WH, Löbenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm. 2007;65:346 -353.
3. Deerojanawong J, Manuyakorn W, Prapphal N, Harnruthakorn C, Sritippayawan S, Samransamruajkit R. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. Pediatr Pulmonol. 2005;39:466-472.
4. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs. 2000;60:1141-1178.
5. Martonen TB, Schroeter JD, Fleming JS. 3D in silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis. J Pharm Sci. 2007;96:603- 617.
6. Bouwman AM, Heijstra MP, Schaefer NC, Duiverman EJ, Lesouëf PN, Devadason SG. Improved efficiency of budesonide nebulization using surface-active agents. Drug Deliv. 2006;13:357-363.
7. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs. 2007;9:185-194.
8. Charman S, Perry C, Chiu F, McIntosh K, Prankerd R, Charman W. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006;95:256 -267.
9. McIntosh MP, Schwarting N, Rajewski RA. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation. J Pharm Sci. 2004;93:2585-2594.
10. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic- pituitaryadrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118 -127.
11. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: comparison with the "gold standard" technique. Chest. 2007;131:410-414.
12. Alving K, Weitzberg E, Lundberg J. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6:1368 -1370.
13. Crater S, Peters E, Martin M, Murphy A, Platts-Mills T. Expired nitric oxide and airway obstruction in asthma patients with an acute exacerbation. Am J Respir Crit Care Med. 1999;159:806-811.
14. Kharitonov S, Yates D, Barnes P. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996;153:454-457.
15. Massaro A, Gaston B, Kita D, Fanta C, Stamler J, Drazen J. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995;152:800-803.
16. Kharitonov S, Donnelly L, Montuschi P, Corradi M, Collins J, Barnes P. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax. 2002;57: 889-896.
17. van den Toorn LM, Prins JB, de Jongste JC, et al. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respir Med. 2005;99:779 -787.
18. Currie GP, Syme-Grant NJ, McFarlane LC, Carey FA, Lipworth BJ. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy. 2003;58: 602-607.
19. Fardon TC, Burns P, Barnes ML, Lipworth BJ. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006; 96:422- 430.
20. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med. 2006;100:785-794.
21. Lipworth BJ, Sims EJ, Das SK, Buck H, Paterson M. Dose-response comparison of budesonide dry powder inhalers using adenosine mono-phosphate bronchial challenge. Ann Allergy Asthma Immunol. 2005;94: 675-681.
22. Menzies D, Nair A, Fardon T, Barnes M, Burns P, Lipworth B. An in vivo and in vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber. Ann Allergy Asthma Immunol. 2007;98:471- 479.
23. Ozbek OY, Turktas I, Bakirtas A, Bideci A. Evaluation of hypothalamicpituitary-adrenal axis suppression by low-dose (0.5 microg) and standard-dose (250 microg) adrenocorticotropic hormone (ACTH) tests in asthmatic children treated with inhaled corticosteroid. J Pediatr Endocrinol Metab. 2006;19:1015-1023.
24. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159: 941-955.
25. Wilson AM, Lipworth BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax. 1999;54:20 -26.
26. Lockwood SF, O'Malley S, Mosher GL. Improved aqueous solubility of crystalline astaxanthin (3,3′-dihydroxy-beta, beta-carotene-4,4′- dione) by Captisol (sulfobutyl ether beta-cyclodextrin). J Pharm Sci. 2003;92: 922-926.
27. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electro-encephalographic and hemodynamic study in a porcine model. Anesth Analg. 2003;97:72-79.
28. Velaga S, Bergh S, Carlfors J. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process. Eur J Pharm Sci. 2004;21:501-509.
29. Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm. 2005;61:115-125.
30. Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56:944 -948.
31. Williamson PA, Menzies D, Nair A, Tutuncu A, Lipworth BJ. A proof-of-concept study to evaluate the anti inflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol. 2009;102:161-167.